Contents

Search

triple negative breast cancer; (ER-, PR-, HER2-)

Laboratory: - see breast cancer Management: - triple negative (ER/PR receptor negative, HER2 negative) breast cancer responds to neoadjuvant chemothrapy [1] - anthracycline-base chemotherapy for early stage triple-negative breast cancer (ER-, PR-, HER2-) [1] - neoadjuvant chemotherapy for triple negative tumors uses standard chemotherapy (see chemotherapy for breast cancer) [1] - atezolizumab (Tecentriq) FDA-approved for treatment of unresectable locally advanced or metastatic triple-negative breast cancer in tumors expressing PD-L1 [2] - also see breast cancer

General

breast cancer

References

  1. Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 18.
  2. FDA Approval Notice. March 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm